Skip to main content

Advertisement

Table 1 Characteristics of 1860 patients with NSCLC according to smoking status

From: Proportion and clinical features of never-smokers with non-small cell lung cancer

Variable Never-smokers [cases (%)] Ever-smokers [cases (%)] P
Total 707 (38.0) 1153 (62.0)  
Sex    <0.001
 Men 115 (16.3) 1088 (94.4)  
 Women 592 (83.7) 65 (5.6)  
Histologic subtype    <0.001
 Adenocarcinoma 635 (89.8) 518 (44.9)  
 Squamous cell carcinoma 25 (3.5) 483 (41.9)  
 Others 47 (6.7) 152 (13.2)  
ECOG PS    <0.001
 0 379 (53.6) 427 (37.0)  
 1 269 (38.1) 558 (48.4)  
 2 43 (6.1) 131 (11.4)  
 3 15 (2.1) 31 (2.7)  
 4 1 (0.1) 6 (0.5)  
Symptoms at diagnosis    <0.001
 Asymptomatic 417 (59.0) 487 (42.2)  
 Symptomatic 290 (41.0) 666 (57.8)  
Driver mutations    
 EGFR mutations (n = 1284) 353 (57.8) 164 (24.4) <0.001
 KRAS mutations (n = 1089) 29 (5.8) 57 (9.6) 0.021
 ALK rearrangements (n = 1288) 47 (7.8) 19 (2.8) <0.001
Stage    <0.001
 I 261 (36.9) 295 (25.6)  
 II 54 (7.6) 153 (13.3)  
 III 115 (16.3) 293 (25.4)  
 IV 277 (39.2) 412 (35.7)  
Treatment    <0.001
 Antitumor 654 (92.5) 983 (85.3)  
 Supportive/unknown 53 (7.5) 170 (14.7)  
  1. NSCLC non-small cell lung cancer, ECOG Eastern Cooperative Oncology Group, PS performance status, EGFR epidermal growth factor receptor, KRAS Kirsten rat sarcoma viral oncogene homolog, ALK anaplastic lymphoma kinase